Tag Archive for: board of directors

Link Biologics strengthens Board with drug discovery expert Dr Niall Martin to advance its TSG-6-based therapeutic pipeline

/in

Dr Martin brings over two decades of leadership in translational science, drug discovery and biotech strategy and entrepreneurship Strengthens Link’s position as it advances its proprietary TSG-6-based therapeutic pipeline towards the clinic  London, UK – 24 February 2026 – Link Biologics (“Link” or “the Company”), the biotech company developing first-in-class TSG-6-based therapies, that have a unique […]

Read more

Blue Cell Therapeutics appoints highly experienced pharma and biotech executive Olav Hellebø as Chairman of the Board of Directors

/in

Seasoned executive with three decades of experience in pharma and biotech Biotech board experience from Cytovation ASA, Antev Ltd, and Calliditas Therapeutics, and governance / senior leadership experience from UCB, Novartis and Schering-Plough (now Merck) Appointment comes as Blue Cell looks to progress its lead candidate, allogeneic stem cell treatment BlueC-231, into Phase 1/2a clinical […]

Read more

Asgard Therapeutics strengthens its Board of Directors and Advisory Board with leading experts in drug development and cancer immunotherapy

/in

Highly experienced biopharma executive Dr Cristina Csimma joins Asgard’s Board of Directors, while esteemed immunologists Prof Ignacio Melero and Prof Brian Brown join Advisory Board Appointments strengthen Asgard’s team as it progresses IND-enabling studies for its lead asset AT-108 – a first-in-class, off-the-shelf cell reprogramming therapy that leads to personalized and potent anti-cancer immune responses […]

Read more

Novo Holdings appoints four new members to its Board of Directors further strengthening global perspectives and strategic capabilities

/in

May 15, 2025 – Novo Holdings is pleased to announce the appointments of Jun Sung Kim, Lars Green, N.P. “Narv” Narvekar and Torsten Sløk to its Board of Directors, effective May 14, 2025. These distinguished leaders bring a broad range of investment expertise spanning both U.S. and international markets, further strengthening the Board’s global perspectives […]

Read more

Vicebio Advances Clinical Study of RSV/hMPV Bivalent Vaccine & Strengthens Board with Appointments of World Class Veterans

/in

Vicebio enters the second stage of its Phase 1 Clinical Study of its lead candidate VXB-241  The Clinical Study, an actively controlled Proof of Concept Phase 1 conducted in target population aged 60+, is progressing as planned with initial data expected by mid-2025 Moncef Slaoui, former Chief Scientific Advisor of Operation Warp Speed & former […]

Read more